ArticleBMC cancer2017
Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 243 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
243 citing papers in PubMed, 2 syntheses or guidelines pooled it, 382 citations in OpenAlex.
- Prognostic value of IGFBP2 in various cancers: a systematic review and meta-analysis.Cancer medicine · 2022Pooled it
- Diagnostic value of circulating lncRNAs for gastric cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Clinical application of thioredoxin reductase as a novel biomarker in liver cancer.Scientific reports · 2021Trial
- Pretreatment multiphasic contrast-enhanced CT predicts tumor regression grade and survival in locally advanced gastric cancer.Abdominal radiology (New York) · 2026Article
- Conducting Polymer-Nanomaterial Hybrids for Cancer Diagnostics.Biosensors · 2026Review
- Diagnostic utility of postmortem serum tumor markers for identifying primary malignancies: A forensic evaluation of six markers.Forensic science, medicine, and pathology · 2026Article
- Inverse co-variation of circulating PIWIL2 and PIWIL4 in gastric adenocarcinoma: an exploratory ELISA-based study.Clinical proteomics · 2026Article
- Metabolic remodeling by circular RNAs in gastric tumorigenesis: From mechanisms to biomarker discovery (Review).International journal of oncology · 2026Review
- Clinical implications of lactylation modification in digestive system tumors (Review).Oncology letters · 2026Review
- Liquid biopsies for the diagnosis of early-stage gastric cancer: A 5-year systematic review.The journal of liquid biopsy · 2026Review
- Clinical value and regulatory role of lncRNA HOXB-AS3 in gastric cancer.World journal of surgical oncology · 2026Article
- Serum Protein Profiling of Patients at Risk to Develop Gastric Disease Based on a DSC Test.International journal of molecular sciences · 2026Article
- Establishment of a Gastric Cancer Diagnostic Model Based on the Combined Evaluation of Peripheral Blood Immune-inflammatory Nutritional Indicators and Tumor Markers.Journal of cancer prevention · 2026Article
- Article
- A liquid biopsy-based multi-methylation marker panel for minimally invasive gastric cancer screening.Clinical epigenetics · 2026Article
- Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study.Medicine · 2026Article
- LINC 02086, a novel biomarker for early detection of gastric cancer and a target for cancer therapy.Cell death and differentiation · 2026Article
- CXCL12 and eotaxin are independent prognostic serum biomarkers in gastric cancer.Scientific reports · 2026Article
- [Vertebral body metastases : From the clarification of back pain to the treatment decision].Unfallchirurgie (Heidelberg, Germany) · 2026Review
- Development and validation of a diagnostic machine learning model for gastric cancer risk based on double-negative T cell-related features.Cancer cell international · 2026Article
183 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe diagnostic and prognostic significance of carcinoembryonic antigen (CEA), carbohydrate associated antigen 19-9 (CA19-9), alpha-fetoprotein (AFP) and cancer antigen 125 (CA125) in early gastric cancer have not been investigated yet. Thus, the present study aimed to explore the diagnostic and prognostic significance of the four tumor markers for early gastric cancer.
methodsFrom September 2008 to March 2015, 587 early gastric cancer patients were given radical gastrectomy in our center. The clinicopathological characteristics were recorded. The association between levels of CEA and CA19-9 and clinicopathological characteristics and prognosis of patients were analyzed.
resultsThere were 444 men (75.6%) and 143 women (24.4%). The median age was 57 years (ranged 21-85). The 1-, 3- and 5-year overall survival rate was 99.1%, 96.8% and 93.1%, respectively. The positive rate of CEA, CA19-9, AFP and CA125 was 4.3%, 4.8%, 1.5% and 1.9%, respectively. The positive rate of all markers combined was 10.4%. The associations between the clinicopathological features and levels of CEA and CA19-9 were analyzed. No significant association was found between CEA level and clinicopathological features. However, elevated CA19-9 level was correlated with female gender and presence of lymph node metastasis. Age > 60 years old, presence of lymph node metastasis and elevation of CEA level were independent risk factors for poor prognosis of early gastric cancer.
conclusionsThe positive rates of CEA, CA19-9, APF and CA125 were relatively low for early gastric cancer. Elevation of CA19-9 level was associated with female gender and presence of lymph node metastasis. Elevation of CEA level was an independent risk factor for the poor prognosis of early gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.